M&A / successionCH·1mo ago✦ enriched
Swiss HBM Healthcare plans to sell Swixx Biopharma for $1.7 billion | AKM EN
HBM Healthcare is exploring options for Swixx Biopharma, including a potential sale valued at about 1.5 billion Swiss francs ($1.7B), with Jefferies and Centerview Partners advising.
WATCH· 54intent / 100